董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeff Dykan | 男 | Director | 67 | 未披露 | 40.91 | 2026-02-27 |
| Ehud Geller | 男 | Chairman of the Board and Chief Executive Officer and Director | 78 | 424.20万美元 | 133.29 | 2026-02-27 |
| Keith Valentine | 男 | Director | 56 | 未披露 | 3.75 | 2026-02-27 |
| Efraim Cohen Arazi | 男 | Director | 70 | 未披露 | 未持股 | 2026-02-27 |
| Pini Ben Elazar | 男 | Director | 52 | 33.60万美元 | 18.38 | 2026-02-27 |
| Susan Alpert | 女 | Director | 76 | 未披露 | 未持股 | 2026-02-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ori Gon | 男 | Chief Financial Officer | 44 | 未披露 | 未持股 | 2026-02-27 |
| Ehud Geller | 男 | Chairman of the Board and Chief Executive Officer and Director | 78 | 424.20万美元 | 133.29 | 2026-02-27 |
| Arie Gordashnikov | 男 | Chief Accounting Officer | 42 | 11.30万美元 | 未持股 | 2026-02-27 |
| Galit Reske | 女 | Chief Medical Officer | 54 | 未披露 | 未持股 | 2026-02-27 |
董事简历
中英对照 | 中文 | 英文- Jeff Dykan
-
Jeff Dykan，他曾一直任职Rewalk Robotics Ltd.的董事会（2006年以来），也一直担任Rewalk Robotics Ltd.的董事会主席（2009年以来）。他被Rewalk Robotics Ltd.的股东SCP Vitalife公司任命。他一直担任Vitalife公司（2002年以来）及其继任基金会（SCP Vitalife，以色列风险投资基金）（2007年以来）的共同企业普通合伙人的董事。加入Vitalife公司之前，他曾担任BitBand公司的主席兼首席执行官（从2001年到2002年）。他是the American Institute of CPAs的成员，持有New York University的会计和管理学士学位，以及计算机应用程序工商管理硕士学位。
Jeff Dykan has served on Regentis Biomaterials Ltd.'s Board of Directors since 2005. He was appointed by Regentis Biomaterials Ltd.'s shareholder SCP Vitalife. Since 2002 Mr. Dykan has been a director of Vitalife Partners Management LP, the general partner of Vitalife, and since 2007 has been a director of its successor fund, SCP Vitalife GP, the corporate general partner of the common general partner of SCP Vitalife Partners II L.P. and its affiliate SCP Vitalife Partners (Israel) II L.P. He has also served as a managing member of SCP Vitalife Management Company, LLC and SCP Vitalife Management Israel Ltd., which by contract provides certain management services to the common general partner of SCP Vitalife. Mr. Dykan was a member of the American Institute of Certified Public Accountants from 1982 through 2021 and holds a B.Sc. in accounting and management and an M.B.A. in computer applications, both from New York University. - Jeff Dykan，他曾一直任职Rewalk Robotics Ltd.的董事会（2006年以来），也一直担任Rewalk Robotics Ltd.的董事会主席（2009年以来）。他被Rewalk Robotics Ltd.的股东SCP Vitalife公司任命。他一直担任Vitalife公司（2002年以来）及其继任基金会（SCP Vitalife，以色列风险投资基金）（2007年以来）的共同企业普通合伙人的董事。加入Vitalife公司之前，他曾担任BitBand公司的主席兼首席执行官（从2001年到2002年）。他是the American Institute of CPAs的成员，持有New York University的会计和管理学士学位，以及计算机应用程序工商管理硕士学位。
- Jeff Dykan has served on Regentis Biomaterials Ltd.'s Board of Directors since 2005. He was appointed by Regentis Biomaterials Ltd.'s shareholder SCP Vitalife. Since 2002 Mr. Dykan has been a director of Vitalife Partners Management LP, the general partner of Vitalife, and since 2007 has been a director of its successor fund, SCP Vitalife GP, the corporate general partner of the common general partner of SCP Vitalife Partners II L.P. and its affiliate SCP Vitalife Partners (Israel) II L.P. He has also served as a managing member of SCP Vitalife Management Company, LLC and SCP Vitalife Management Israel Ltd., which by contract provides certain management services to the common general partner of SCP Vitalife. Mr. Dykan was a member of the American Institute of Certified Public Accountants from 1982 through 2021 and holds a B.Sc. in accounting and management and an M.B.A. in computer applications, both from New York University.
- Ehud Geller
-
Ehud Geller自2007年起担任Regentis Biomaterials Ltd.董事会主席，自2025年12月31日起担任Regentis Biomaterials Ltd.首席执行官。Geller先生还自2008年11月起担任PRF技术有限公司（纳斯达克：PRFX）的董事会主席，并自2024年9月起担任其临时首席执行官。自1995年以来，Geller博士一直担任Medica Venture Partners的普通合伙人。1979年至1985年间，盖勒博士担任梯瓦制药（NYSE：TEVA）制药部门总裁兼梯瓦集团执行副总裁。在Teva，他领导了对Ikapharm Ltd.的收购。他曾于1985年至1990年担任Interpharm Laboratories，Ltd.的总裁兼首席执行官。在这些年里，他还担任过以色列制药商协会的负责人，以及特拉维夫证券交易所的董事会成员。Geller博士拥有化学工程学士学位、哥伦比亚大学/德雷克塞尔研究所MBA学位和费城德雷克塞尔研究所制药/化学工程博士学位。1995年起任Medica Venture Partners普通合伙人。Geller先生被选为董事会主席是因为他在医药行业领导和成长中的公司方面拥有丰富的经验，以及他的重要领导经验。他领导公司管理层的经验以及对Regentis Biomaterials Ltd.业务的深入了解，使他能够在Regentis Biomaterials Ltd.持续面临的复杂业务事项上提供宝贵的领导。盖勒博士将把大约50%的时间用于公司，担任执行董事长兼首席执行官，因为他目前也受雇于Medica Venture Partners。
Ehud Geller has served as the Chairman of Regentis Biomaterials Ltd.'s Board of Directors since 2007 and as Regentis Biomaterials Ltd.'s Chief Executive Officer since December 31, 2025. Mr. Geller has also served as the Chairman of the Board of Directors of PRF Technologies Ltd. (Nasdaq: PRFX) since November 2008, and serves as its Interim Chief Executive Officer since September 2024. Since 1995, Dr. Geller has served as the General Partner of Medica Venture Partners. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical industry and his significant leadership experience. His experience leading the Company's management and the depth of his knowledge of Regentis Biomaterials Ltd.'s business enable him to provide valuable leadership on complex business matters that Regentis Biomaterials Ltd. face on an ongoing basis. Dr. Geller will devote approximately 50% of his time to the Company, as an executive Chairman and Chief Executive Officer, as he also is currently employed by Medica Venture Partners. - Ehud Geller自2007年起担任Regentis Biomaterials Ltd.董事会主席，自2025年12月31日起担任Regentis Biomaterials Ltd.首席执行官。Geller先生还自2008年11月起担任PRF技术有限公司（纳斯达克：PRFX）的董事会主席，并自2024年9月起担任其临时首席执行官。自1995年以来，Geller博士一直担任Medica Venture Partners的普通合伙人。1979年至1985年间，盖勒博士担任梯瓦制药（NYSE：TEVA）制药部门总裁兼梯瓦集团执行副总裁。在Teva，他领导了对Ikapharm Ltd.的收购。他曾于1985年至1990年担任Interpharm Laboratories，Ltd.的总裁兼首席执行官。在这些年里，他还担任过以色列制药商协会的负责人，以及特拉维夫证券交易所的董事会成员。Geller博士拥有化学工程学士学位、哥伦比亚大学/德雷克塞尔研究所MBA学位和费城德雷克塞尔研究所制药/化学工程博士学位。1995年起任Medica Venture Partners普通合伙人。Geller先生被选为董事会主席是因为他在医药行业领导和成长中的公司方面拥有丰富的经验，以及他的重要领导经验。他领导公司管理层的经验以及对Regentis Biomaterials Ltd.业务的深入了解，使他能够在Regentis Biomaterials Ltd.持续面临的复杂业务事项上提供宝贵的领导。盖勒博士将把大约50%的时间用于公司，担任执行董事长兼首席执行官，因为他目前也受雇于Medica Venture Partners。
- Ehud Geller has served as the Chairman of Regentis Biomaterials Ltd.'s Board of Directors since 2007 and as Regentis Biomaterials Ltd.'s Chief Executive Officer since December 31, 2025. Mr. Geller has also served as the Chairman of the Board of Directors of PRF Technologies Ltd. (Nasdaq: PRFX) since November 2008, and serves as its Interim Chief Executive Officer since September 2024. Since 1995, Dr. Geller has served as the General Partner of Medica Venture Partners. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical industry and his significant leadership experience. His experience leading the Company's management and the depth of his knowledge of Regentis Biomaterials Ltd.'s business enable him to provide valuable leadership on complex business matters that Regentis Biomaterials Ltd. face on an ongoing basis. Dr. Geller will devote approximately 50% of his time to the Company, as an executive Chairman and Chief Executive Officer, as he also is currently employed by Medica Venture Partners.
- Keith Valentine
-
Keith Valentine自2015年起担任Regentis Biomaterials Ltd.的董事会成员。瓦伦丁先生拥有超过30年的直接脊柱和骨科行业经验。自2025年5月以来，瓦伦丁先生一直担任Intrinsic Therapeutics，Inc.（即Intrinsic Therapeutics）的总裁、首席执行官和董事会成员，该公司是一家医疗技术公司，致力于通过减少再手术的再次手术来改变患有大型环状缺损的腰椎间盘切除患者的护理标准。在加入Intrinsic Therapeutics之前，Valentine先生最近担任Orthofix，Inc.（纳斯达克：OFIX）的总裁兼首席执行官，该公司是一家全球脊柱和骨科公司，该公司于2023年与SeaSpine，Inc.（简称SeaSpine）合并。在2023年合并之前，Valentine先生从2015年开始担任SeaSpine的首席执行官兼总裁，SeaSpine是一家全球医疗技术公司，专注于治疗脊柱疾病的手术解决方案的设计、开发和商业化。在加入SeaSpine之前，Valentine先生曾于2001年至2015年在NuVasive，Inc.担任各种领导职务，包括最近担任总裁兼首席运营官，在此之前担任营销、开发和运营方面的高级管理职务。从1992年到2000年，瓦伦丁先生在美敦力 Spine LLC担任领导职务，最近担任该公司市场营销副总裁。他目前担任LocateBio Ltd.的董事会主席，LocateBio Ltd.是一家英国私营医疗技术公司，拥有行业领先的rhBMP2递送和组织支架能力。Valentine先生自2024年7月起担任Alphatec Holdings, Inc.（纳斯达克：ATEC）或Alphatec的董事。在担任Alphatec董事之前，Valentine先生从2023年10月起担任他们董事会的特别顾问，直到2024年当选。Valentine先生此前曾于2015年至2024年在SI Bone，Inc（纳斯达克：SIBN）的董事会任职，该公司是骶髂关节疾病微创手术治疗和脊柱手术骶骨固定的开发商。Valentine先生拥有西密歇根大学管理和生物医学科学学士学位。
Keith Valentine has served on Regentis Biomaterials Ltd.'s Board of Directors since 2015. Mr. Valentine has over 30 years of direct spine and orthopedics industry experience. Mr. Valentine has served as President, Chief Executive Officer and member of the board of directors of Intrinsic Therapeutics, Inc., or Intrinsic Therapeutics, a medical technology company driving to change the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations, since May 2025. Prior to joining Intrinsic Therapeutics, Mr. Valentine was most recently President and Chief Executive Officer of Orthofix, Inc. (Nasdaq: OFIX), a global spine and orthopedics company, following its merger with SeaSpine, Inc., or SeaSpine, in 2023. Prior to the merger in 2023, Mr. Valentine served as Chief Executive Officer and President of SeaSpine, a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders, beginning in 2015. Prior to joining SeaSpine, Mr. Valentine served in various leadership capacities at NuVasive, Inc. from 2001 to 2015, including, most recently, as President and Chief Operating Officer, and before that, in senior executive roles in marketing, development and operations. From 1992 through 2000, Mr. Valentine held leadership positions with Medtronic Spine LLC, most recently as that company's Vice President of Marketing. He currently serves as Chairman of the board of directors of LocateBio Ltd., a private UK MedTech company with industry leading rhBMP 2 delivery and tissue scaffold capabilities. Mr. Valentine has served as a director of Alphatec Holdings, Inc. (Nasdaq: ATEC), or Alphatec, since July 2024. Prior to his time as a director of Alphatec, Mr. Valentine served as special advisor to their board of directors from October 2023 until his election in 2024. Mr. Valentine previously served on the board of directors of SI Bone, Inc (Nasdaq: SIBN), a developer of minimally invasive surgical treatments for sacroiliac joint disorders and sacral fixation for spine surgery, from 2015 until 2024. Mr. Valentine holds a B.B.A. degree in Management and Biomedical Sciences from Western Michigan University. - Keith Valentine自2015年起担任Regentis Biomaterials Ltd.的董事会成员。瓦伦丁先生拥有超过30年的直接脊柱和骨科行业经验。自2025年5月以来，瓦伦丁先生一直担任Intrinsic Therapeutics，Inc.（即Intrinsic Therapeutics）的总裁、首席执行官和董事会成员，该公司是一家医疗技术公司，致力于通过减少再手术的再次手术来改变患有大型环状缺损的腰椎间盘切除患者的护理标准。在加入Intrinsic Therapeutics之前，Valentine先生最近担任Orthofix，Inc.（纳斯达克：OFIX）的总裁兼首席执行官，该公司是一家全球脊柱和骨科公司，该公司于2023年与SeaSpine，Inc.（简称SeaSpine）合并。在2023年合并之前，Valentine先生从2015年开始担任SeaSpine的首席执行官兼总裁，SeaSpine是一家全球医疗技术公司，专注于治疗脊柱疾病的手术解决方案的设计、开发和商业化。在加入SeaSpine之前，Valentine先生曾于2001年至2015年在NuVasive，Inc.担任各种领导职务，包括最近担任总裁兼首席运营官，在此之前担任营销、开发和运营方面的高级管理职务。从1992年到2000年，瓦伦丁先生在美敦力 Spine LLC担任领导职务，最近担任该公司市场营销副总裁。他目前担任LocateBio Ltd.的董事会主席，LocateBio Ltd.是一家英国私营医疗技术公司，拥有行业领先的rhBMP2递送和组织支架能力。Valentine先生自2024年7月起担任Alphatec Holdings, Inc.（纳斯达克：ATEC）或Alphatec的董事。在担任Alphatec董事之前，Valentine先生从2023年10月起担任他们董事会的特别顾问，直到2024年当选。Valentine先生此前曾于2015年至2024年在SI Bone，Inc（纳斯达克：SIBN）的董事会任职，该公司是骶髂关节疾病微创手术治疗和脊柱手术骶骨固定的开发商。Valentine先生拥有西密歇根大学管理和生物医学科学学士学位。
- Keith Valentine has served on Regentis Biomaterials Ltd.'s Board of Directors since 2015. Mr. Valentine has over 30 years of direct spine and orthopedics industry experience. Mr. Valentine has served as President, Chief Executive Officer and member of the board of directors of Intrinsic Therapeutics, Inc., or Intrinsic Therapeutics, a medical technology company driving to change the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations, since May 2025. Prior to joining Intrinsic Therapeutics, Mr. Valentine was most recently President and Chief Executive Officer of Orthofix, Inc. (Nasdaq: OFIX), a global spine and orthopedics company, following its merger with SeaSpine, Inc., or SeaSpine, in 2023. Prior to the merger in 2023, Mr. Valentine served as Chief Executive Officer and President of SeaSpine, a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders, beginning in 2015. Prior to joining SeaSpine, Mr. Valentine served in various leadership capacities at NuVasive, Inc. from 2001 to 2015, including, most recently, as President and Chief Operating Officer, and before that, in senior executive roles in marketing, development and operations. From 1992 through 2000, Mr. Valentine held leadership positions with Medtronic Spine LLC, most recently as that company's Vice President of Marketing. He currently serves as Chairman of the board of directors of LocateBio Ltd., a private UK MedTech company with industry leading rhBMP 2 delivery and tissue scaffold capabilities. Mr. Valentine has served as a director of Alphatec Holdings, Inc. (Nasdaq: ATEC), or Alphatec, since July 2024. Prior to his time as a director of Alphatec, Mr. Valentine served as special advisor to their board of directors from October 2023 until his election in 2024. Mr. Valentine previously served on the board of directors of SI Bone, Inc (Nasdaq: SIBN), a developer of minimally invasive surgical treatments for sacroiliac joint disorders and sacral fixation for spine surgery, from 2015 until 2024. Mr. Valentine holds a B.B.A. degree in Management and Biomedical Sciences from Western Michigan University.
- Efraim Cohen Arazi
-
Efraim 科恩 Arazi自2008年起担任Rainbow Medical的联合创始人兼首席执行官，该公司是以色列领先的医疗器械创新公司。2004年至2006年，科恩 Arazi先生担任IntecPharma Ltd.的首席执行官和联合创始人，并自2006年起担任Collplant有限公司的董事长。自2005年以来，科恩 Arazi先生曾在多家生物技术/医疗技术公司担任董事，目前在PainReform有限公司（PRFX）担任董事。科恩 Arazi先生是位于华盛顿州西雅图的Immunex Corporation的高级副总裁运营主管，直到2002年该公司被安进收购，在那里他担任副总裁兼加利福尼亚州TO站点的总经理。科恩 Arazi先生于1988年至2000年期间在瑞士和以色列的默沙东雪兰诺集团任职。科恩 Arazi先生获得以色列耶路撒冷希伯来大学理学硕士学位。
Efraim Cohen Arazi was the Co Founder & Chief Executive Officer of Rainbow Medical, a leading Israeli medical device innovation house since 2008. From 2004 to 2006 Mr. Cohen Arazi served as the Chief Executive Officer and Co Founder of IntecPharma Ltd. and as Chairman of CollPlant Ltd. since 2006. Mr. Cohen Arazi served as a director in numerous biotech/medtech companies since 2005, and currently serves as a director in PainReform Ltd. (Nasdaq: PRFX ). Mr. Cohen Arazi was the Senior VP Head of Operations at Immunex Corporation in Seattle, Washington until 2002 when it was acquired by Amgen, where he served as VP and General Manager of the TO site in California. Mr. Cohen Arazi served at Merck Serono Group in Switzerland and Israel between 1988 and 2000. Mr. Cohen Arazi received a M.Sc. degree from the Hebrew University of Jerusalem, Israel. - Efraim 科恩 Arazi自2008年起担任Rainbow Medical的联合创始人兼首席执行官，该公司是以色列领先的医疗器械创新公司。2004年至2006年，科恩 Arazi先生担任IntecPharma Ltd.的首席执行官和联合创始人，并自2006年起担任Collplant有限公司的董事长。自2005年以来，科恩 Arazi先生曾在多家生物技术/医疗技术公司担任董事，目前在PainReform有限公司（PRFX）担任董事。科恩 Arazi先生是位于华盛顿州西雅图的Immunex Corporation的高级副总裁运营主管，直到2002年该公司被安进收购，在那里他担任副总裁兼加利福尼亚州TO站点的总经理。科恩 Arazi先生于1988年至2000年期间在瑞士和以色列的默沙东雪兰诺集团任职。科恩 Arazi先生获得以色列耶路撒冷希伯来大学理学硕士学位。
- Efraim Cohen Arazi was the Co Founder & Chief Executive Officer of Rainbow Medical, a leading Israeli medical device innovation house since 2008. From 2004 to 2006 Mr. Cohen Arazi served as the Chief Executive Officer and Co Founder of IntecPharma Ltd. and as Chairman of CollPlant Ltd. since 2006. Mr. Cohen Arazi served as a director in numerous biotech/medtech companies since 2005, and currently serves as a director in PainReform Ltd. (Nasdaq: PRFX ). Mr. Cohen Arazi was the Senior VP Head of Operations at Immunex Corporation in Seattle, Washington until 2002 when it was acquired by Amgen, where he served as VP and General Manager of the TO site in California. Mr. Cohen Arazi served at Merck Serono Group in Switzerland and Israel between 1988 and 2000. Mr. Cohen Arazi received a M.Sc. degree from the Hebrew University of Jerusalem, Israel.
- Pini Ben Elazar
-
Pini Ben Elazar作为首席执行官和董事是一位非常有经验的高管，在医疗保健行业拥有超过25年的成功经验。他是一位变革和增长领导者，在独特的具有挑战性的情况下提供财政、战略和运营领导，并且是一位利用有效和创造性思维和沟通技巧的专业谈判者。自2003年以来，Ben Elazar先生目前担任以色列Clalit Health Services技术转让办公室Mor Research Applications的首席执行官。他还是其中多家医疗保健公司的董事：Ceretrieve、Enox、DreamMed Diabetes、Data2Life、NGS、APX眼科、斑马医视、Galil Ofek。Ben Elazar先生自1996年起拥有美国罗德岛州普罗维登斯强生威尔士大学MBA学位，罗德岛州普罗维登斯强生威尔士大学酒店管理学士学位，并于2019年完成了哈佛商学院8400健康网络领导力项目的学习。
Pini Ben Elazar is a very experienced executive as a Chief Executive Officer and as a director with over 25 years of successful experience in the healthcare industry. He is a change and growth leader providing fiscal, strategic and operations leadership in uniquely challenging situations, and is a professional negotiator harnessing effective and creative thinking and communicating skills. Mr. Ben Elazar currently serves as the Chief Executive Officer of Mor Research Applications, Tech Transfer Office of Clalit Health Services in Israel since 2003. He is also a director in numerous healthcare companies among them: Ceretrieve, Enox, DreamMed Diabetes, Data2Life, NGS, APX ophthalmology, Zebra Medical Vision, and Galil Ofek. Mr. Ben Elazar holds an MBA from Johnson& Wales University, Providence, RI since 1996, a B.Sc in Hospitality Management, Johnson & Wales University, Providence, RI, and completed the studies of the 8400 Health Network Leadership Program, Harvard Business School, in 2019. - Pini Ben Elazar作为首席执行官和董事是一位非常有经验的高管，在医疗保健行业拥有超过25年的成功经验。他是一位变革和增长领导者，在独特的具有挑战性的情况下提供财政、战略和运营领导，并且是一位利用有效和创造性思维和沟通技巧的专业谈判者。自2003年以来，Ben Elazar先生目前担任以色列Clalit Health Services技术转让办公室Mor Research Applications的首席执行官。他还是其中多家医疗保健公司的董事：Ceretrieve、Enox、DreamMed Diabetes、Data2Life、NGS、APX眼科、斑马医视、Galil Ofek。Ben Elazar先生自1996年起拥有美国罗德岛州普罗维登斯强生威尔士大学MBA学位，罗德岛州普罗维登斯强生威尔士大学酒店管理学士学位，并于2019年完成了哈佛商学院8400健康网络领导力项目的学习。
- Pini Ben Elazar is a very experienced executive as a Chief Executive Officer and as a director with over 25 years of successful experience in the healthcare industry. He is a change and growth leader providing fiscal, strategic and operations leadership in uniquely challenging situations, and is a professional negotiator harnessing effective and creative thinking and communicating skills. Mr. Ben Elazar currently serves as the Chief Executive Officer of Mor Research Applications, Tech Transfer Office of Clalit Health Services in Israel since 2003. He is also a director in numerous healthcare companies among them: Ceretrieve, Enox, DreamMed Diabetes, Data2Life, NGS, APX ophthalmology, Zebra Medical Vision, and Galil Ofek. Mr. Ben Elazar holds an MBA from Johnson& Wales University, Providence, RI since 1996, a B.Sc in Hospitality Management, Johnson & Wales University, Providence, RI, and completed the studies of the 8400 Health Network Leadership Program, Harvard Business School, in 2019.
- Susan Alpert
-
Susan Alpert目前是SFADC LLC（又名SFA Regulatory，LLC）自2019年以来的主要负责人，该公司是一家专注于将医疗设备和其他医疗产品放入全球市场所需战略的单人公司。她曾担任美敦力公司全球监管部门的公司高级副总裁，在此之前担任C.R. Bard，Inc.的监管科学副总裁。她此前曾在美国FDA工作，在涉及药物、设备和放射健康以及食品的中心担任过各种管理职务。1993年至1999年任装置评价办公室主任。Alpert博士是一名微生物学家和儿科医生，专门研究传染病。她在纽约市哥伦比亚大学巴纳德学院完成本科学位，拥有纽约大学生物医学科学硕士和博士学位，以及迈阿密大学（佛罗里达州）医学学位。Alpert博士是多个非营利和营利委员会的成员。
Susan Alpert is currently the principle of SFADC LLC (aka SFA Regulatory, LLC) since 2019, a one person firm focused on the strategies needed to place medical devices and other medical products into the global market. She was a Corporate Senior Vice President for Global Regulatory at Medtronic, Inc. and prior to that VP Regulatory Science at C.R. Bard, Inc. She previously worked at the U.S. FDA where she held a variety of management positions in the centers dealing with drugs, devices and radiological health, and foods. She was Director of the Office of Device Evaluation from 1993 1999. Dr. Alpert is a microbiologist and pediatrician with a specialty in infectious diseases. She completed her undergraduate degree at Barnard College, Columbia University in New York City, holds a master's degree and Ph.D. in Biomedical Sciences from New York University and a medical degree from the University of Miami (Florida). Dr. Alpert is a member of several non profit and for profit boards. - Susan Alpert目前是SFADC LLC（又名SFA Regulatory，LLC）自2019年以来的主要负责人，该公司是一家专注于将医疗设备和其他医疗产品放入全球市场所需战略的单人公司。她曾担任美敦力公司全球监管部门的公司高级副总裁，在此之前担任C.R. Bard，Inc.的监管科学副总裁。她此前曾在美国FDA工作，在涉及药物、设备和放射健康以及食品的中心担任过各种管理职务。1993年至1999年任装置评价办公室主任。Alpert博士是一名微生物学家和儿科医生，专门研究传染病。她在纽约市哥伦比亚大学巴纳德学院完成本科学位，拥有纽约大学生物医学科学硕士和博士学位，以及迈阿密大学（佛罗里达州）医学学位。Alpert博士是多个非营利和营利委员会的成员。
- Susan Alpert is currently the principle of SFADC LLC (aka SFA Regulatory, LLC) since 2019, a one person firm focused on the strategies needed to place medical devices and other medical products into the global market. She was a Corporate Senior Vice President for Global Regulatory at Medtronic, Inc. and prior to that VP Regulatory Science at C.R. Bard, Inc. She previously worked at the U.S. FDA where she held a variety of management positions in the centers dealing with drugs, devices and radiological health, and foods. She was Director of the Office of Device Evaluation from 1993 1999. Dr. Alpert is a microbiologist and pediatrician with a specialty in infectious diseases. She completed her undergraduate degree at Barnard College, Columbia University in New York City, holds a master's degree and Ph.D. in Biomedical Sciences from New York University and a medical degree from the University of Miami (Florida). Dr. Alpert is a member of several non profit and for profit boards.
高管简历
中英对照 | 中文 | 英文- Ori Gon
Ori Gon自2026年2月起担任Regentis Biomaterials Ltd.的首席财务官。Gon先生在公共和私营企业以及医疗技术领域拥有超过15年的财务领导经验。最近，从2022年3月开始，他在Tactile Mobility担任首席财务官，这是一家专注于先进汽车和移动应用的传感和数据分析公司。在此之前，他曾在ReWalk Robotics公司担任高级财务领导职务，该公司现已在纳斯达克上市，是Lifeward Ltd.，该公司是一家于2015年8月至2022年2月期间为下肢残疾个人开发可穿戴机器人外骨骼的先驱公司。在其职业生涯的早期，他曾于2012年11月至2015年8月担任On Track Innovations Ltd.的财务总监，该公司是一家在纳斯达克和Neuer Markt上市的金融科技公司。他的职业生涯始于2008年11月至2012年11月的毕马威以色列审计公司。Gon先生在耶路撒冷希伯来大学获得会计和金融学士学位。
Ori Gon has been Regentis Biomaterials Ltd.'s Chief Financial Officer since February 2026.Most recently, starting in March 2022 he served as Chief Financial Officer at Tactile Mobility, a sensing and data analytics company focused on advanced automotive and mobility applications. Prior to that, he held senior financial leadership roles at ReWalk Robotics, Inc., now Nasdaq listed Lifeward Ltd., a pioneer in wearable robotic exoskeletons for individuals with lower limb disabilities from August 2015 until February 2022. Earlier in his career, he was Controller at On Track Innovations Ltd., a Nasdaq and Neuer Markt listed fintech company from November 2012 until August 2015. He began his professional career as an auditor at KPMG Israel from November 2008 until November 2012. Mr. Gon received his Bachelor's Degree in Accounting and Finance from the Hebrew University of Jerusalem.- Ori Gon自2026年2月起担任Regentis Biomaterials Ltd.的首席财务官。Gon先生在公共和私营企业以及医疗技术领域拥有超过15年的财务领导经验。最近，从2022年3月开始，他在Tactile Mobility担任首席财务官，这是一家专注于先进汽车和移动应用的传感和数据分析公司。在此之前，他曾在ReWalk Robotics公司担任高级财务领导职务，该公司现已在纳斯达克上市，是Lifeward Ltd.，该公司是一家于2015年8月至2022年2月期间为下肢残疾个人开发可穿戴机器人外骨骼的先驱公司。在其职业生涯的早期，他曾于2012年11月至2015年8月担任On Track Innovations Ltd.的财务总监，该公司是一家在纳斯达克和Neuer Markt上市的金融科技公司。他的职业生涯始于2008年11月至2012年11月的毕马威以色列审计公司。Gon先生在耶路撒冷希伯来大学获得会计和金融学士学位。
- Ori Gon has been Regentis Biomaterials Ltd.'s Chief Financial Officer since February 2026.Most recently, starting in March 2022 he served as Chief Financial Officer at Tactile Mobility, a sensing and data analytics company focused on advanced automotive and mobility applications. Prior to that, he held senior financial leadership roles at ReWalk Robotics, Inc., now Nasdaq listed Lifeward Ltd., a pioneer in wearable robotic exoskeletons for individuals with lower limb disabilities from August 2015 until February 2022. Earlier in his career, he was Controller at On Track Innovations Ltd., a Nasdaq and Neuer Markt listed fintech company from November 2012 until August 2015. He began his professional career as an auditor at KPMG Israel from November 2008 until November 2012. Mr. Gon received his Bachelor's Degree in Accounting and Finance from the Hebrew University of Jerusalem.
- Ehud Geller
Ehud Geller自2007年起担任Regentis Biomaterials Ltd.董事会主席，自2025年12月31日起担任Regentis Biomaterials Ltd.首席执行官。Geller先生还自2008年11月起担任PRF技术有限公司（纳斯达克：PRFX）的董事会主席，并自2024年9月起担任其临时首席执行官。自1995年以来，Geller博士一直担任Medica Venture Partners的普通合伙人。1979年至1985年间，盖勒博士担任梯瓦制药（NYSE：TEVA）制药部门总裁兼梯瓦集团执行副总裁。在Teva，他领导了对Ikapharm Ltd.的收购。他曾于1985年至1990年担任Interpharm Laboratories，Ltd.的总裁兼首席执行官。在这些年里，他还担任过以色列制药商协会的负责人，以及特拉维夫证券交易所的董事会成员。Geller博士拥有化学工程学士学位、哥伦比亚大学/德雷克塞尔研究所MBA学位和费城德雷克塞尔研究所制药/化学工程博士学位。1995年起任Medica Venture Partners普通合伙人。Geller先生被选为董事会主席是因为他在医药行业领导和成长中的公司方面拥有丰富的经验，以及他的重要领导经验。他领导公司管理层的经验以及对Regentis Biomaterials Ltd.业务的深入了解，使他能够在Regentis Biomaterials Ltd.持续面临的复杂业务事项上提供宝贵的领导。盖勒博士将把大约50%的时间用于公司，担任执行董事长兼首席执行官，因为他目前也受雇于Medica Venture Partners。
Ehud Geller has served as the Chairman of Regentis Biomaterials Ltd.'s Board of Directors since 2007 and as Regentis Biomaterials Ltd.'s Chief Executive Officer since December 31, 2025. Mr. Geller has also served as the Chairman of the Board of Directors of PRF Technologies Ltd. (Nasdaq: PRFX) since November 2008, and serves as its Interim Chief Executive Officer since September 2024. Since 1995, Dr. Geller has served as the General Partner of Medica Venture Partners. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical industry and his significant leadership experience. His experience leading the Company's management and the depth of his knowledge of Regentis Biomaterials Ltd.'s business enable him to provide valuable leadership on complex business matters that Regentis Biomaterials Ltd. face on an ongoing basis. Dr. Geller will devote approximately 50% of his time to the Company, as an executive Chairman and Chief Executive Officer, as he also is currently employed by Medica Venture Partners.- Ehud Geller自2007年起担任Regentis Biomaterials Ltd.董事会主席，自2025年12月31日起担任Regentis Biomaterials Ltd.首席执行官。Geller先生还自2008年11月起担任PRF技术有限公司（纳斯达克：PRFX）的董事会主席，并自2024年9月起担任其临时首席执行官。自1995年以来，Geller博士一直担任Medica Venture Partners的普通合伙人。1979年至1985年间，盖勒博士担任梯瓦制药（NYSE：TEVA）制药部门总裁兼梯瓦集团执行副总裁。在Teva，他领导了对Ikapharm Ltd.的收购。他曾于1985年至1990年担任Interpharm Laboratories，Ltd.的总裁兼首席执行官。在这些年里，他还担任过以色列制药商协会的负责人，以及特拉维夫证券交易所的董事会成员。Geller博士拥有化学工程学士学位、哥伦比亚大学/德雷克塞尔研究所MBA学位和费城德雷克塞尔研究所制药/化学工程博士学位。1995年起任Medica Venture Partners普通合伙人。Geller先生被选为董事会主席是因为他在医药行业领导和成长中的公司方面拥有丰富的经验，以及他的重要领导经验。他领导公司管理层的经验以及对Regentis Biomaterials Ltd.业务的深入了解，使他能够在Regentis Biomaterials Ltd.持续面临的复杂业务事项上提供宝贵的领导。盖勒博士将把大约50%的时间用于公司，担任执行董事长兼首席执行官，因为他目前也受雇于Medica Venture Partners。
- Ehud Geller has served as the Chairman of Regentis Biomaterials Ltd.'s Board of Directors since 2007 and as Regentis Biomaterials Ltd.'s Chief Executive Officer since December 31, 2025. Mr. Geller has also served as the Chairman of the Board of Directors of PRF Technologies Ltd. (Nasdaq: PRFX) since November 2008, and serves as its Interim Chief Executive Officer since September 2024. Since 1995, Dr. Geller has served as the General Partner of Medica Venture Partners. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical industry and his significant leadership experience. His experience leading the Company's management and the depth of his knowledge of Regentis Biomaterials Ltd.'s business enable him to provide valuable leadership on complex business matters that Regentis Biomaterials Ltd. face on an ongoing basis. Dr. Geller will devote approximately 50% of his time to the Company, as an executive Chairman and Chief Executive Officer, as he also is currently employed by Medica Venture Partners.
- Arie Gordashnikov
Arie Gordashnikov，自2022年10月起担任首席财务官。他自2018年起担任Shimony Yosef Certified Public Accountant（ISR。）或Shimony的首次公开发行（IPO）和并购部门主管。Gordashnikov先生在高科技和生物技术公司的会计、审计和财务方面拥有超过13年的经验。在加入Shimony之前，Gordashnikov先生是Ernst & Young Israel的审计经理。Gordashnikov先生拥有特拉维夫大学财务管理MBA学位、耶路撒冷希伯来大学会计和经济学学士学位，自2012年以来一直是持牌注册会计师。
Arie Gordashnikov has been Regentis Biomaterials Ltd.'s Chief Accounting Officer since February 2026 and was formerly Regentis Biomaterials Ltd.'s Chief Financial Officer from October 2022 until January 2026. He has served as Head of Initial Public Offering, or IPO, and Mergers and Acquisitions Department at Shimony Yosef Certified Public Accountant (Isr.), or Shimony, since 2018. Mr. Gordashnikov has over 15 years' experience in accounting, auditing and finance of Hi Tech and biotechnology companies. Before joining Shimony, Mr. Gordashnikov was an audit manager at Ernst & Young Israel. Mr. Gordashnikov holds an MBA degree from Tel Aviv University in financial management, a B.A. in Accounting and Economics from Hebrew University of Jerusalem and has been a licensed CPA since 2012.- Arie Gordashnikov，自2022年10月起担任首席财务官。他自2018年起担任Shimony Yosef Certified Public Accountant（ISR。）或Shimony的首次公开发行（IPO）和并购部门主管。Gordashnikov先生在高科技和生物技术公司的会计、审计和财务方面拥有超过13年的经验。在加入Shimony之前，Gordashnikov先生是Ernst & Young Israel的审计经理。Gordashnikov先生拥有特拉维夫大学财务管理MBA学位、耶路撒冷希伯来大学会计和经济学学士学位，自2012年以来一直是持牌注册会计师。
- Arie Gordashnikov has been Regentis Biomaterials Ltd.'s Chief Accounting Officer since February 2026 and was formerly Regentis Biomaterials Ltd.'s Chief Financial Officer from October 2022 until January 2026. He has served as Head of Initial Public Offering, or IPO, and Mergers and Acquisitions Department at Shimony Yosef Certified Public Accountant (Isr.), or Shimony, since 2018. Mr. Gordashnikov has over 15 years' experience in accounting, auditing and finance of Hi Tech and biotechnology companies. Before joining Shimony, Mr. Gordashnikov was an audit manager at Ernst & Young Israel. Mr. Gordashnikov holds an MBA degree from Tel Aviv University in financial management, a B.A. in Accounting and Economics from Hebrew University of Jerusalem and has been a licensed CPA since 2012.
- Galit Reske
Galit Reske于2026年2月被任命为Regentis Biomaterials Ltd.的首席医疗官，预计入职日期为2026年4月。从2017年到2026年，Reske博士担任CartiHeal的临床运营总监，她在Agili C的临床和监管推进中发挥了核心作用，一种新型软骨和骨软骨修复植入物。在她任职期间，她领导了该公司的IDE Pivotal研究，在美国、欧洲和以色列管理30多个地点的临床试验，并监督临床操作、临床法规、数据管理和医学写作的各个方面。此前，她曾在TechnoSTAT担任临床部门经理等高级临床职务，负责为制药和医疗器械公司管理跨多个治疗领域的全球I期IV期临床研究。她还曾担任Bioovo Technologies的医疗产品专家和CRO Consultants的临床试验经理。Reske博士拥有耶路撒冷希伯来大学分子生物学博士学位。
Galit Reske was appointed as Regentis Biomaterials Ltd.'s Chief Medical Officer in February 2026, with an anticipated employment start date in April 2026. From 2017 to 2026, Dr. Reske served as Director of Clinical Operations at CartiHeal, where she played a central role in the clinical and regulatory advancement of Agili C, a novel cartilage and osteochondral repair implant. During her tenure, she led the company's IDE Pivotal Study, managing clinical trials across more than 30 sites in the U.S., Europe, and Israel, and oversaw all aspects of clinical operations, clinical regulations, data management, and medical writing. Prior, she held senior clinical positions including Manager of Clinical Department at TechnoSTAT, where she managed global Phase I IV clinical studies across multiple therapeutic areas for pharmaceutical and medical device companies. She also served as Medical Product Specialist at Biovo Technologies and Clinical Trials Manager at CRO Consultants. Dr. Reske holds a PhD in Molecular Biology from the Hebrew University of Jerusalem.- Galit Reske于2026年2月被任命为Regentis Biomaterials Ltd.的首席医疗官，预计入职日期为2026年4月。从2017年到2026年，Reske博士担任CartiHeal的临床运营总监，她在Agili C的临床和监管推进中发挥了核心作用，一种新型软骨和骨软骨修复植入物。在她任职期间，她领导了该公司的IDE Pivotal研究，在美国、欧洲和以色列管理30多个地点的临床试验，并监督临床操作、临床法规、数据管理和医学写作的各个方面。此前，她曾在TechnoSTAT担任临床部门经理等高级临床职务，负责为制药和医疗器械公司管理跨多个治疗领域的全球I期IV期临床研究。她还曾担任Bioovo Technologies的医疗产品专家和CRO Consultants的临床试验经理。Reske博士拥有耶路撒冷希伯来大学分子生物学博士学位。
- Galit Reske was appointed as Regentis Biomaterials Ltd.'s Chief Medical Officer in February 2026, with an anticipated employment start date in April 2026. From 2017 to 2026, Dr. Reske served as Director of Clinical Operations at CartiHeal, where she played a central role in the clinical and regulatory advancement of Agili C, a novel cartilage and osteochondral repair implant. During her tenure, she led the company's IDE Pivotal Study, managing clinical trials across more than 30 sites in the U.S., Europe, and Israel, and oversaw all aspects of clinical operations, clinical regulations, data management, and medical writing. Prior, she held senior clinical positions including Manager of Clinical Department at TechnoSTAT, where she managed global Phase I IV clinical studies across multiple therapeutic areas for pharmaceutical and medical device companies. She also served as Medical Product Specialist at Biovo Technologies and Clinical Trials Manager at CRO Consultants. Dr. Reske holds a PhD in Molecular Biology from the Hebrew University of Jerusalem.